[The effects of thromboxane A2 synthetase inhibitor on chronic rejection of kidney transplantation].
There has been no useful treatments for chronic vascular rejection (CVR) after kidney transplantation until now. Recently, however, some reports have suggested that the thromboxane A2 synthetase inhibitor, OKY-046, is useful in reducing proteinuria in nephrotic syndrome and preventing progression of CVR. Five patients with CVR (serum creatinine range: 1.7-2.6 mg/dl) were treated with OKY-046 for over one year and the effect of OKY-046 was evaluated. One patient developed acute rejection and another renal hypertension during this study. Except for the cases of acute rejection and renal hypertension, serum creatinine slightly decreased in 1 case and remained unchanged in 2 cases. Urinary excretion of protein and thromboxane B2 decreased significantly but prostaglandin E2 did not change in the treatment of the deterioration with OKY-046. We concluded that OKY-046 was effective in preventing graft function and decreasing urinary protein excretion in kidney transplant recipients with CVR.
Imanishi
M
M
Department of Urology, Kinki University School of Medicine.
Ikegami
M
M
Nishioka
T
T
Ishii
T
T
Uemura
T
T
Kunikata
S
S
Kanda
H
H
Matsuura
T
T
Akiyama
T
T
Kurita
T
T
D000179:Acrylates / Q000494:pharmacology*; D002908:Chronic Disease; D005260:Female; D006084:Graft Rejection / Q000187:drug effects*; D006801:Humans; D007668:Kidney / Q000473:pathology; D016030:Kidney Transplantation; D008297:Male; D008689:Methacrylates / Q000494:pharmacology*; D011458:Prostaglandins E / Q000652:urine; D011507:Proteinuria; D013929:Thromboxane B2 / Q000652:urine; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D000179:Acrylates; D008689:Methacrylates; D011458:Prostaglandins E; D013929:Thromboxane B2; D013930:Thromboxane-A Synthase; C034364:ozagrel